WO2023012264A3 - Activateur pharmacologique et/ou genetique pour son utilisation pour preserver et regenerer la structure et la fonction musculaire en bloquant la senescence - Google Patents

Activateur pharmacologique et/ou genetique pour son utilisation pour preserver et regenerer la structure et la fonction musculaire en bloquant la senescence Download PDF

Info

Publication number
WO2023012264A3
WO2023012264A3 PCT/EP2022/071914 EP2022071914W WO2023012264A3 WO 2023012264 A3 WO2023012264 A3 WO 2023012264A3 EP 2022071914 W EP2022071914 W EP 2022071914W WO 2023012264 A3 WO2023012264 A3 WO 2023012264A3
Authority
WO
WIPO (PCT)
Prior art keywords
activator
function
senescence
preserving
blocking
Prior art date
Application number
PCT/EP2022/071914
Other languages
English (en)
Other versions
WO2023012264A2 (fr
Inventor
Valentina TAGLIETTI
Frédéric RELAIX
Original Assignee
Association Francaise Contre Les Myopathies
Université Paris-Est Créteil (Upec)
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association Francaise Contre Les Myopathies, Université Paris-Est Créteil (Upec), Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Association Francaise Contre Les Myopathies
Priority to EP22765409.2A priority Critical patent/EP4380965A2/fr
Publication of WO2023012264A2 publication Critical patent/WO2023012264A2/fr
Publication of WO2023012264A3 publication Critical patent/WO2023012264A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un activateur pour son utilisation pour préserver et régénérer la structure et la fonction musculaire. L'invention se caractérise en ce que ledit activateur est un activateur de la voie de signalisation du récepteur de la thyréostimuline (TSHR) dans des cellules souches musculaires (cellules satellites) pour préserver et régénérer la structure et la fonction musculaire en bloquant la sénescence. L'invention concerne également une combinaison d'un activateur pharmacologique pour son utilisation selon l'invention et d'un activateur génétique pour son utilisation selon l'invention, ainsi qu'un vecteur adénoviral comprenant une séquence protéique du récepteur de la thyréostimuline (TSHR) de SEQ ID NO :1, ou une séquence nucléotidique du TSHR de SEQ ID NO :2 pour son utilisation à titre de médicament.
PCT/EP2022/071914 2021-08-04 2022-08-04 Activateur pharmacologique et/ou genetique pour son utilisation pour preserver et regenerer la structure et la fonction musculaire en bloquant la senescence WO2023012264A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22765409.2A EP4380965A2 (fr) 2021-08-04 2022-08-04 Activateur pharmacologique et/ou genetique pour son utilisation pour preserver et regenerer la structure et la fonction musculaire en bloquant la senescence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR2108489 2021-08-04
FR2108489A FR3126005A1 (fr) 2021-08-04 2021-08-04 Activateur pharmacologique et/ou génétique pour son utilisation pour préserver et régénérer la structure et la fonction musculaire en bloquant la sénescence

Publications (2)

Publication Number Publication Date
WO2023012264A2 WO2023012264A2 (fr) 2023-02-09
WO2023012264A3 true WO2023012264A3 (fr) 2023-03-30

Family

ID=80122380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/071914 WO2023012264A2 (fr) 2021-08-04 2022-08-04 Activateur pharmacologique et/ou genetique pour son utilisation pour preserver et regenerer la structure et la fonction musculaire en bloquant la senescence

Country Status (3)

Country Link
EP (1) EP4380965A2 (fr)
FR (1) FR3126005A1 (fr)
WO (1) WO2023012264A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009137A1 (fr) * 1989-12-20 1991-06-27 Basil Rapoport Recepteur de thyrotropine recombinant
JP2021103947A (ja) * 2019-12-26 2021-07-26 ヤマサ醤油株式会社 変異が導入された甲状腺刺激ホルモン受容体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018155913A1 (fr) 2017-02-21 2018-08-30 성균관대학교산학협력단 Procédé de différenciation en cellule de muscle squelettique à l'aide d'un composé de faible poids moléculaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009137A1 (fr) * 1989-12-20 1991-06-27 Basil Rapoport Recepteur de thyrotropine recombinant
JP2021103947A (ja) * 2019-12-26 2021-07-26 ヤマサ醤油株式会社 変異が導入された甲状腺刺激ホルモン受容体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCINTOSH L.M. ET AL: "Hypothyroidism prolongs and increases mdx muscle precursor proliferation and delays myotube formation in normal and dystrophic limb muscle", vol. 73, no. 3-4, 1 March 1995 (1995-03-01), CA, pages 181 - 190, XP055929874, ISSN: 0829-8211, Retrieved from the Internet <URL:http://dx.doi.org/10.1139/o95-022> DOI: 10.1139/o95-022 *
NEUMANN SUSANNE ET AL: "Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice", vol. 106, no. 30, 28 July 2009 (2009-07-28), pages 12471 - 12476, XP055929513, ISSN: 0027-8424, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708975/pdf/zpq12471.pdf> DOI: 10.1073/pnas.0904506106 *

Also Published As

Publication number Publication date
FR3126005A1 (fr) 2023-02-10
EP4380965A2 (fr) 2024-06-12
WO2023012264A2 (fr) 2023-02-09

Similar Documents

Publication Publication Date Title
EP2875042B1 (fr) Peptides anti-inflammatoires et composition en contenant
Venables et al. Abundance of an endogenous retroviral envelope protein in placental trophoblasts suggests a biological function
Hullin et al. Calcium channel beta subunit heterogeneity: functional expression of cloned cDNA from heart, aorta and brain.
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2003051272A2 (fr) Compositions pharmaceutiques et methodes permettant la modulation de l&#39;activite des lymphocytes t par les hormones i et ii de liberation de la gonadotrophine (gnrh-i et gnrh-ii), leur adherence, leur migration et leur extravasation
WO2013167299A1 (fr) Peptides anti-inflammatoires et composition comprenant ceux-ci
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
RU2017143580A (ru) Улучшенные последовательности уриказы и способы лечения
WO2023012264A3 (fr) Activateur pharmacologique et/ou genetique pour son utilisation pour preserver et regenerer la structure et la fonction musculaire en bloquant la senescence
WO2001051673A8 (fr) Methodes et compositions destinees a l&#39;inhibition d&#39;evenements associes a la fusion membranaire, y compris la transmission du vih
KUWANO et al. Molecular cloning and nucleotide sequence of cDNA coding for rat brain cholecystokinin precursor
Mair et al. The neuropeptide F (NPF) encoding gene from the cestode, Moniezia expansa
Wang et al. Variation in the expression of orexin and orexin receptors in the rat hypothalamus during the estrous cycle, pregnancy, parturition, and lactation
Gutman et al. Angiotensin increases microsomal (Na+− K+-ATPase activity in several tissues
WO2006014422A3 (fr) Polynucleotide codant un polypeptide trim-cyp, compositions associees et procedes d&#39;utilisation
WO2005072766A3 (fr) Peptides se liant aux proteines hsp90
Risbridger et al. Inhibin-related proteins in rat prostate
BRPI0318594B8 (pt) proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico
NZ583429A (en) Peptides and proteins capable of inhibiting and/or preventing mast cell activation
Vona et al. Genetics, geography, and culture: the population of S. Pietro Island (Sardinia, Italy)
EP1801211A4 (fr) Peptide liant une molécule hla, fragment d&#39;adn codant pour celui-ci et vecteur recombinant
Shin et al. Characterization of shark complement factor I gene (s): Genomic analysis of a novel shark-specific sequence
WO2022090543A8 (fr) Résistance au peronospora dans spinacia oleracea
EP3333180B1 (fr) Peptides anti-inflammatoires et composition les comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22765409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022765409

Country of ref document: EP

Effective date: 20240304